Sequence and construct
Primary sequence, terminal chemistry, conjugation, metal coordination and formulation define the entity.
Peptide medicine · Clinic Terrain Bali
Medical peptide care in Bali, guided by clinical need rather than trends.
Clinic Terrain connects molecule-level expertise, an individual medical decision, controlled sourcing, product-specific documentation and longitudinal follow-up in one peptide pathway.
For people looking for peptide expertise, physician supervision, verifiable product quality and a protocol built around their actual objective in Bali.See the clinical peptide pathway →
One clinical system · Four ways to enter
The clinic connects expertise, product and patient.
Begin with your objective, a molecule, a quality question or a practical access question. Every route reconnects to the same physician decision and product-specific evidence standard.
01 · CLINICAL PATHWAY
Start from the person, not the vial.
Assessment, molecule selection or refusal, product verification and longitudinal follow-up.
See the clinical pathway →02 · MOLECULAR EXPERTISEUnderstand what each molecule actually does.
Eleven biochemistry-first monographs with evidence boundaries and counterevidence.
Enter the monograph library →03 · PRODUCT CONTROLConnect source, presentation, batch and COA.
What is verified, what remains unproven and why documentation cannot transfer.
See the quality framework →04 · PRACTICAL ACCESSUnderstand price, availability and inclusions.
Transparent guides after the clinical and product-quality gates are understood.
View practical access →Molecule index · Clinic Terrain editorial series
See the field.
Molecule by molecule.
Each visual marks a distinct clinical question, not a product promise. Availability, suitability and the documentation attached to any proposed supply are confirmed individually.
CLINIC TERRAINMetabolicRetatrutide
Metabolic signalling
Open the medical brief
Retatrutide is a single engineered, long-acting peptide that activates GIP, GLP-1 and glucagon receptors. It is a calibrated multi-receptor pharmacology, not three drugs added together.
GIP and GLP-1 receptor activity integrates glucose-dependent insulin secretion and appetite reduction. Glucagon-receptor activity may increase energy expenditure and lipid mobilisation while changing glycaemic and cardiovascular demands. Receptor balance, exposure and escalation are integral to the effect.
In a 338-participant phase 2 obesity trial, mean weight change at week 48 ranged from −8.7% at 1 mg to −24.2% at 12 mg, versus −2.1% with placebo. A 98-participant MASLD substudy found large liver-fat reductions at week 24. Sponsor-reported phase 3 topline results remain labelled as such until full peer-reviewed reports are available.
Gastrointestinal events were dose-related and heart rate increased dose-dependently before declining. Scale weight does not resolve lean mass, nutritional adequacy, gallbladder or pancreatic symptoms, renal stress during severe gastrointestinal illness, or long-term outcomes.
CLINIC TERRAINMetabolicTirzepatide
Incretin medicine
Open the medical brief
Tirzepatide is a long-acting dual GIP/GLP-1 receptor agonist with a mature human development programme. Results belong to the exact construct, formulation and exposure studied.
Integrated GIP and GLP-1 receptor signalling changes appetite, glucose-dependent insulin secretion, gastric physiology and energy intake. Dose, adherence, diet, resistance stimulus, sleep and concomitant therapy remain causal parts of the observed trajectory.
SURMOUNT-1 randomised 2,539 adults. Mean weight change at week 72 was −15.0%, −19.5% and −20.9% with 5, 10 and 15 mg, versus −3.1% with placebo. Body-composition analysis estimated that approximately 75% of weight lost was fat mass and 25% lean mass on average.
Gastrointestinal adverse events and treatment discontinuation were more frequent during active treatment, particularly during escalation. A favourable average does not guarantee preserved function, adequate nutrition or an acceptable response for an individual.
CLINIC TERRAINRepairBPC-157
Tissue repair questions
Open the medical brief
BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence described in gastric-juice research. Identity, route and exposure must remain explicit.
Experimental literature reports gastrointestinal integrity, angiogenic signalling, nitric-oxide pathways and effects in tendon, ligament and drug-injury models. The breadth is hypothesis-rich but does not create a universal repair mechanism.
A small retrospective knee-pain series reported subjective improvement without randomisation, blinding, standardised function or systematic imaging. A 2025 intravenous pilot in two previously exposed adults detected no clinical or laboratory safety signal; two participants cannot establish efficacy or safety. No adequate prospective controlled clinical trial has yet established BPC-157 efficacy for tendon, ligament, muscle, gastrointestinal injury or recovery outcomes.
Human effect size, repeated-use tolerability and rare-event risk remain unresolved. Angiogenic and tissue-remodelling biology is not automatically favourable and requires context in proliferative disease, unexplained lesions and active bleeding.
CLINIC TERRAINRepairTB-500 (Ac-LKKTETQ)
Recovery biology
Open the medical brief
In this monograph TB-500 denotes the N-terminally acetylated 17–23 fragment Ac-LKKTETQ. Full-length thymosin-β4 is a separate 43-residue entity. The terminal acetyl group is part of identity; LKKTETQ alone is incomplete.
Full-length thymosin-β4 regulates actin dynamics, migration, inflammatory signalling, angiogenesis and wound biology. Those mechanisms cannot automatically be assigned to Ac-LKKTETQ.
Controlled wound literature concerns defined full-length thymosin-β4 preparations and specific routes. Adequate human evidence for systemic Ac-LKKTETQ administration has not been established.
Evidence from full-length thymosin-β4, a preconditioned-cell study or another route is not direct evidence for systemic Ac-LKKTETQ. Sequence and terminal chemistry change degradation and target interaction.
CLINIC TERRAINNeuroendocrineCJC-1295 with DAC
Growth-hormone axis
Open the medical brief
Here CJC-1295 means the DAC construct: a tetrasubstituted GRF(1–29) analogue bearing a drug-affinity complex that binds albumin. A shorter-acting no-DAC construct is a different entity and cannot inherit its pharmacokinetics.
CJC-1295 with DAC engages the GHRH receptor and prolongs stimulation of pulsatile growth-hormone secretion, with downstream IGF-1 elevation. Target engagement does not itself establish recovery, body-composition, sleep or longevity benefit.
Human studies establish prolonged GH-axis engagement and preservation of pulsatility. They do not establish patient-relevant outcomes in recovery, body composition or healthy ageing.
An IGF-1 rise is a pharmacodynamic signal, not a clinical success. Oedema, paraesthesia, arthralgia, glycaemic deterioration, sleep-apnoea context and growth signalling remain biologically relevant boundaries.
CLINIC TERRAINNeuroendocrineIpamorelin
Secretagogue pathway
Open the medical brief
Ipamorelin is a defined pentapeptide growth-hormone secretagogue. Its molecular identity and evidence are independent of every other GH-axis peptide.
Ipamorelin activates the ghrelin receptor GHSR1a and produces growth-hormone release. Receptor selectivity defines mechanism but does not guarantee a meaningful clinical outcome.
A phase 2 postoperative-ileus trial enrolled 117 patients. The primary endpoint was 25.3 hours with ipamorelin versus 32.6 hours with placebo and was not statistically significant (p=0.15).
The negative controlled trial is direct evidence that verified receptor pharmacology does not guarantee clinical translation for a chosen indication. It constrains that claim without negating GHSR1a engagement.
CLINIC TERRAINMitochondrialMOTS-c
Mitochondrial signalling
Open the medical brief
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. Endogenous MOTS-c and an administered preparation are related scientific questions, not interchangeable evidence.
Experimental work connects MOTS-c with folate-cycle stress, de novo purine synthesis, AMPK activation, glucose utilisation and mitochondrial-to-nuclear signalling.
Human studies associate circulating MOTS-c with metabolic status, PCOS, insulin resistance, muscle biology and exercise. These observations illuminate endogenous physiology but do not establish therapeutic efficacy.
At the evidence cutoff, no adequate randomised human efficacy trial of native exogenous MOTS-c was identified. Association and exercise response cannot substitute for administered-product exposure.
CLINIC TERRAINImmuneThymosin alpha-1
Immune modulation
Open the medical brief
Thymosin alpha-1 is a defined 28-amino-acid thymic peptide with a larger human literature than most non-incretin peptides in this collection.
The mechanistic programme includes dendritic-cell function, Toll-like receptor pathways, T-cell maturation and immune restoration. ‘Immune boosting’ is too imprecise to represent this biology.
Trials in chronic viral hepatitis and oncology have produced heterogeneous results. A large phase 3 sepsis trial randomised 1,106 patients: 28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo (HR 0.99; p=0.93).
The neutral sepsis result is decisive counterevidence to a broad mortality claim in unselected sepsis. It does not erase molecular mechanism or answer every narrower immune phenotype.
CLINIC TERRAINNeuroregulatorySelank
Neuroimmune questions
Open the medical brief
Selank is a synthetic heptapeptide related to tuftsin. The clinically reported intranasal route and any proposed parenteral route are different exposure experiments.
Proposed actions include GABAergic modulation, neurotrophic pathways and immune–neural communication. Much of the causal programme remains preclinical.
A comparative report in 60 patients with anxiety and somatoform disorders described anxiolytic and mild cognitive effects relative to phenazepam, but accessible reporting leaves randomisation, blinding, allocation and endpoint hierarchy insufficiently resolved.
Small human reports establish administration and a signal worth studying; they do not establish broad anxiolysis, cognitive enhancement or injectable efficacy.
CLINIC TERRAINNeuroregulatorySemax
Neurotrophic signalling
Open the medical brief
Semax is the defined heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, derived from an ACTH(4–7) motif with a Pro-Gly-Pro extension. It is not ‘Samax’ and it is not a combination.
Preclinical studies report BDNF/TrkB and neuroplasticity-related changes. Network or molecular modulation is target engagement, not proof of cognitive or clinical benefit.
A small resting-state fMRI study included 24 healthy participants and reported network-level change. Small or methodologically limited stroke cohorts have reported clinical signals in treatment contexts that require comparison with modern stroke care.
Imaging change does not establish cognitive benefit, and historical non-equivalent controls do not support a universal neuroprotection claim. Long-term and injectable safety remain unresolved.
CLINIC TERRAINTissue & skinGHK-Cu
Copper peptide biology
Open the medical brief
GHK is glycyl-L-histidyl-L-lysine; GHK-Cu is its Cu(II) complex. GHK, GHK-Cu, free copper and mixtures are not biologically interchangeable. Stoichiometry is part of identity.
The mechanistic programme includes copper binding, extracellular-matrix regulation, fibroblast collagen synthesis, wound biology and gene-expression effects under defined experimental conditions.
Topical cosmetic literature reports signals but products vary. In a 13-participant randomised study after CO₂ laser resurfacing, topical copper tripeptide did not improve objective erythema, wrinkles or overall skin quality, although satisfaction differed.
The controlled topical result constrains the leap from fibroblast biology to guaranteed visible rejuvenation. Topical evidence cannot establish systemic regeneration or injectable benefit.
Peptide identity gate
There is no generic peptide mechanism.
A peptide protocol becomes scientifically interpretable only when the administered molecular entity can be connected to its own target, exposure, physiology and response.
Molecular interaction
Receptor agonism, binding or signalling must belong to that exact entity, not a parent peptide, fragment or commercial nickname.
Route and pharmacology
Proteolysis, albumin binding, clearance and tissue access determine whether the proposed mechanism can be reached.
Individual falsification
A predefined functional or biological measure determines whether to continue, modify or stop the pathway.
Know the molecule before discussing the protocol
Peptides are not one treatment category. Clinic Terrain maintains molecule-specific monographs that separate sequence, targets, exposure, human evidence, counterevidence and unresolved questions. Retatrutide, BPC-157, GHK-Cu, MOTS-c and Selank cannot borrow one another’s mechanism or certainty.
Start with the patient, then accept or refuse the molecule
The objective, history, medication, diagnosis, laboratory context and previous response are assembled before the physician decides whether a peptide is coherent. The outcome may be a protocol, a different starting point or a documented refusal.
Two possible supply routes; one release standard
A finished presentation may be purchased through a documented manufacturer or supplier. A locally prepared presentation may be considered only when the responsible authorised entity, raw-material source, formulation, preparation record and release documentation are all identifiable. Clinic Terrain does not treat local preparation, an invoice or a supplier relationship as proof of molecular quality.
Match the exact product to the exact evidence
Before any final supply is represented as traced, the proposed molecule, formulation, strength, presentation and current lot must be connected to the available analytical record, receipt and storage trail. Identity or purity for another molecule, format or historic lot does not transfer.
Make the response change the next decision
Baseline, product identity, dose, adherence, tolerance, symptoms, biomarkers and functional response remain in one longitudinal record. The physician continues, adapts or stops from observed trajectory rather than from a fixed commercial calendar.
Product proof · connected by molecule
Published COAs sit beside the molecule they actually tested.
NAD+, tirzepatide and retatrutide have retrievable analytical references. BPC-157, GHK-Cu, TB-500 and the other listed peptides are not allowed to borrow those certificates.
Connected clinical library
Peptides, selected for a person and traced to a product.
Molecule-specific expertise, physician selection, controlled sourcing, presentation-specific document matching and longitudinal follow-up.
Direct answers
The practical questions this page resolves.
Where can I access peptides with medical supervision in Bali?
Clinic Terrain begins with a physician-led assessment, then resolves the exact molecule, lawful route, current availability, product identity, matching documentation and follow-up. It is not an anonymous worldwide peptide shop.
Can I buy peptides online from Clinic Terrain?
No anonymous checkout is offered. Start with the molecule or objective; the clinical team confirms whether a physician assessment is required, whether the pathway is appropriate and what can be supplied in Bali.
How much do peptides cost?
Current Clinic Terrain guide prices include retatrutide 10mg at Rp 2,790,000, retatrutide 20mg at Rp 4,800,000, tirzepatide 10mg at Rp 3,200,000 and BPC-157 10mg at Rp 1,050,000. Final price and availability are confirmed after clinical clearance.
Which peptide is best for recovery, weight loss or longevity?
There is no class-wide answer. The exact molecule, mechanism, exposure, individual terrain, evidence boundary and measurable objective must be evaluated separately.
Do you provide peptide consultation in Bali?
Yes. Clinic Terrain coordinates physician-led peptide assessment and follow-up across Bali, including Canggu, Seminyak, Ubud, Uluwatu, Sanur and Nusa Dua. Consultation does not guarantee that a requested molecule will be indicated or supplied.
Evidence position
The evidence is applied to the specific clinical question. It supports an individual assessment; it does not replace diagnosis or guarantee an outcome.
Sources used for this page
Regulatory guidanceWHO: good storage and distribution practices for medical products ↗International principles for documented purchasing, receipt, storage, distribution and supply-chain integrity.Regulatory guidanceICH: harmonised pharmaceutical quality guidelines ↗Quality frameworks covering analytical validation, specifications, stability, manufacturing and pharmaceutical quality systems.Your first message · Where you are + what you need help with